Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Conditions
Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Contact: Principal Investigator (Mohamad Sonbol)Highlands Oncology Group, Fayetteville, Arkansas, United States
Contact: Principal Investigator (Joseph Thaddeus Beck)Rocky Mountain Cancer Centers, Denver, Colorado, United States
Contact: Principal Investigator (Allen Cohn)Hartford Hospital, Hartford, Connecticut, United States
Contact: Principal Investigator (Andrew Salner)Yale New Haven Hospital, New Haven, Connecticut, United States
Contact: Principal Investigator (Pamela Kunz)Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Contact: Principal Investigator (Jason Starr)Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Principal Investigator (Amol Takalkar)St Elizabeth Healthcare, Edgewood, Kentucky, United States
Contact: Principal Investigator (Minsig Choi)LSU Medical Center, New Orleans, Louisiana, United States
Contact: Principal Investigator (Mary Maluccio)Henry Ford Hospital, Detroit, Michigan, United States
Contact: Principal Investigator (Philip A Philip)Mount Sinai Medical Center, New York, New York, United States
Contact: Principal Investigator (Edward Wolin)Piedmont Healthcare, Winston-Salem, North Carolina, United States
Contact: Principal Investigator (Eyal Meiri)Tennessee Oncology, Nashville, Tennessee, United States
Contact: Principal Investigator (Joseph Merriman)TxO Austin Midtown, Austin, Texas, United States
Texas Oncology, Dallas, Texas, United States
Contact: Principal Investigator (Scott Scott Paulson)Virginia Cancer Specialists, Fairfax, Virginia, United States
Contact: Principal Investigator (Gregory Scott Sibley)Virginia Oncology Associates, Norfolk, Virginia, United States
Contact: Principal Investigator (Jedrzej Wykretowicz)Blue Ridge Cancer Center, Wytheville, Virginia, United States
Contact: Principal Investigator (David Buck)Northwest Medical Specialties, Tacoma, Washington, United States
Contact: Principal Investigator (Mohammed N Kanaan)Novartis Investigative Site, Edmonton, Alberta, Canada
Novartis Investigative Site, London, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Bron, France
Novartis Investigative Site, Clichy, France
Novartis Investigative Site, Montpellier, France
Novartis Investigative Site, Nantes, France
Novartis Investigative Site, Pessac, France
Novartis Investigative Site, Toulouse, France
Novartis Investigative Site, Erlangen, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, München, Germany
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Szeged, Hungary
Novartis Investigative Site, Cona, FE, Italy
Novartis Investigative Site, Genova, GE, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Pisa, PI, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Milan, Italy
Novartis Investigative Site, Rotterdam, South Holland, Netherlands
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Gdansk, Poland
Novartis Investigative Site, Gliwice, Poland
Novartis Investigative Site, Krakow, Poland
Novartis Investigative Site, Poznan, Poland
Novartis Investigative Site, Warsaw, Poland
Novartis Investigative Site, Warsaw, Poland
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site, Oviedo, Principality of Asturias, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Salamanca, Spain
Novartis Investigative Site, London, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals